BRPI1013560A2 - métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória - Google Patents
métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatóriaInfo
- Publication number
- BRPI1013560A2 BRPI1013560A2 BRPI1013560A BRPI1013560A BRPI1013560A2 BR PI1013560 A2 BRPI1013560 A2 BR PI1013560A2 BR PI1013560 A BRPI1013560 A BR PI1013560A BR PI1013560 A BRPI1013560 A BR PI1013560A BR PI1013560 A2 BRPI1013560 A2 BR PI1013560A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory bowel
- bowel disease
- prognosis
- predict
- likelihood
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 3
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16923009P | 2009-04-14 | 2009-04-14 | |
| US17845409P | 2009-05-14 | 2009-05-14 | |
| US22045309P | 2009-06-25 | 2009-06-25 | |
| US25506609P | 2009-10-26 | 2009-10-26 | |
| US26290309P | 2009-11-19 | 2009-11-19 | |
| US26532409P | 2009-11-30 | 2009-11-30 | |
| US26572309P | 2009-12-01 | 2009-12-01 | |
| US28635609P | 2009-12-14 | 2009-12-14 | |
| US30078710P | 2010-02-02 | 2010-02-02 | |
| US30206610P | 2010-02-05 | 2010-02-05 | |
| PCT/US2010/030934 WO2010120814A1 (en) | 2009-04-14 | 2010-04-13 | Inflammatory bowel disease prognostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013560A2 true BRPI1013560A2 (pt) | 2018-06-19 |
Family
ID=42401087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013560A BRPI1013560A2 (pt) | 2009-04-14 | 2010-04-13 | métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9732385B2 (pt) |
| EP (2) | EP2960342A1 (pt) |
| AU (1) | AU2010236568B2 (pt) |
| BR (1) | BRPI1013560A2 (pt) |
| CA (1) | CA2758531C (pt) |
| ES (1) | ES2553415T3 (pt) |
| IL (2) | IL215619A (pt) |
| NZ (2) | NZ595471A (pt) |
| WO (1) | WO2010120814A1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US12110555B2 (en) | 2004-12-08 | 2024-10-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| NZ595471A (en) | 2009-04-14 | 2014-01-31 | Nestec Sa | Inflammatory bowel disease prognostics |
| JP2013528389A (ja) * | 2010-06-04 | 2013-07-11 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善させる方法 |
| US8645306B2 (en) * | 2010-07-02 | 2014-02-04 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| WO2012071436A1 (en) * | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
| CA2830351A1 (en) * | 2011-03-25 | 2012-10-04 | Cedars-Sinai Medical Center | Methods of diagnosing ulcerative colitis and crohn's disease |
| EP2689034B1 (en) * | 2011-03-25 | 2016-03-23 | Cedars-Sinai Medical Center | Role of ifng methylation in inflammatory bowel disease |
| WO2012154987A1 (en) * | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| WO2012174293A2 (en) * | 2011-06-14 | 2012-12-20 | Nestec Sa | Methods for identifying inflammatory bowel disease patients with dysplasia or cancer |
| EP2769321B1 (en) * | 2011-10-21 | 2016-06-01 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| CN103958662A (zh) * | 2011-10-24 | 2014-07-30 | 私募蛋白质体公司 | 用于疾病生物标记鉴定和样品质量评价的优选样品处理和加工方案的选择 |
| EP2907061A4 (en) * | 2012-10-10 | 2016-07-27 | Abbvie Biotechnology Ltd | MANAGEMENT OF HEALTH SERVICES |
| RU2517069C1 (ru) * | 2012-11-21 | 2014-05-27 | Мария Георгиевна Ильяшенко | Способ прогнозирования риска развития рецидива воспалительных заболеваний кишечника |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| USD802608S1 (en) * | 2013-04-25 | 2017-11-14 | Life Technologies Corporation | Display screen with graphical user interface |
| CN105209643A (zh) * | 2013-05-17 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎性肠病的方法 |
| CN105358713B (zh) * | 2013-05-17 | 2020-02-28 | 雪松-西奈医学中心 | 与克罗恩病相关的tnfsf15和dcr3的变体 |
| SG11201509371XA (en) | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific markers for diagnosing irritable bowel syndrome |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| CA2932571A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Methods for predicting post-operative recurrence of crohn's disease |
| MA39804A (fr) | 2014-03-27 | 2017-02-01 | Hoffmann La Roche | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin |
| US10127660B2 (en) * | 2015-12-30 | 2018-11-13 | Case Western Reserve University | Radiomic features on diagnostic magnetic resonance enterography |
| US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
| KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| CN109690314B (zh) * | 2016-05-09 | 2022-08-02 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
| CN109476698B (zh) | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | 基于基因的炎性肠病诊断 |
| EP3273373A1 (en) * | 2016-07-18 | 2018-01-24 | Fresenius Medical Care Deutschland GmbH | Drug dosing recommendation |
| JP6567484B2 (ja) * | 2016-09-29 | 2019-08-28 | 株式会社日立製作所 | 推計モデル構築システム、推計モデル構築方法及びプログラム |
| US20180272065A1 (en) * | 2017-03-24 | 2018-09-27 | Medtronic Minimed, Inc. | Patient management systems and uplift recommendation methods |
| US11162943B2 (en) | 2017-05-31 | 2021-11-02 | Prometheus Biosciences Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| CN109884310B (zh) * | 2017-12-25 | 2022-04-01 | 苏州和锐生物科技有限公司 | 肠道菌外膜多肽、抗体捕获器件及试剂盒 |
| CN109884311B (zh) * | 2017-12-25 | 2022-04-01 | 苏州和锐生物科技有限公司 | 肠杆菌多肽、抗体捕获器件及试剂盒 |
| AU2019325238A1 (en) | 2018-08-21 | 2021-03-18 | Bruce R. Yacyshyn | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
| CA3121162A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| WO2020205911A1 (en) * | 2019-04-01 | 2020-10-08 | Colorado State University Research Foundation | Methods for diagnosing and treating inflammatory bowel disease in companion animals |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| CN120866510A (zh) * | 2019-08-12 | 2025-10-31 | 雷杰纳荣制药公司 | 巨噬细胞刺激1受体(mst1r)变体及其用途 |
| US12394524B2 (en) * | 2020-07-22 | 2025-08-19 | Iterative Scopes, Inc. | Systems and methods for analysis of medical images for scoring of inflammatory bowel disease |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4277250A (en) | 1979-12-10 | 1981-07-07 | Baylor College Of Medicine | Methods for detecting and quantifying occult blood |
| JPH0684970B2 (ja) | 1987-03-31 | 1994-10-26 | 株式会社京都医科学研究所 | 糞便中の潜血検出方法 |
| US5081040A (en) | 1987-06-29 | 1992-01-14 | Helena Laboratories Corporation | Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| JPH0736013B2 (ja) | 1991-04-27 | 1995-04-19 | 一男 田畑 | 潜血検出用試薬 |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| ATE193601T1 (de) | 1993-03-10 | 2000-06-15 | Cedars Sinai Medical Center | Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| US5844107A (en) | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US6074835A (en) | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
| US5932429A (en) * | 1996-04-12 | 1999-08-03 | Cedars-Sinai Medical Center | Methods of diagnosing clinical subtypes of crohn's disease |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| US5916748A (en) * | 1996-04-12 | 1999-06-29 | Cedars-Sinai Medical Center | Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis |
| WO1998037415A1 (en) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| WO2000071096A2 (en) | 1999-05-24 | 2000-11-30 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| FR2802536B1 (fr) | 1999-11-23 | 2003-06-13 | Chru Lille | Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections |
| FR2806739B1 (fr) * | 2000-03-27 | 2005-02-18 | Fond Jean Dausset Ceph | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
| US6821739B2 (en) * | 2000-10-13 | 2004-11-23 | The Regents Of The University Of California | Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens |
| WO2002032396A2 (en) | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
| AU2002227350B2 (en) | 2000-10-30 | 2007-03-22 | Regents Of The University Of Michigan | Nod2 nucleic acids and proteins |
| EP1404712B1 (en) | 2000-10-30 | 2014-06-18 | The Regents Of The University Of Michigan | Nod2 nucleic acids and proteins |
| US7060442B2 (en) * | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
| US20050164929A1 (en) * | 2000-11-06 | 2005-07-28 | Lupine Logic, Inc. | Methods of preventing and treating inflammatory bowel disease |
| EP2071332A1 (en) | 2000-11-14 | 2009-06-17 | Techlab, Inc. | Method for monitoring persons with IBD using total endogeneous lactoferrin as a marker |
| AU2002256398A2 (en) | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| EP1581119B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US20030204507A1 (en) * | 2002-04-25 | 2003-10-30 | Li Jonathan Qiang | Classification of rare events with high reliability |
| US20040053263A1 (en) | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| ATE395596T1 (de) | 2002-10-25 | 2008-05-15 | Techlab Inc | Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon |
| AU2003298703A1 (en) | 2002-11-22 | 2004-06-18 | Emory University | Diagnostic tests and methods for diagnosing inflammatory bowel disease |
| US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| JPWO2004095021A1 (ja) | 2003-04-23 | 2006-07-13 | エーザイ株式会社 | 疾患予後モデルの作成方法、このモデルを用いた疾患予後予測方法、このモデルによる予後予測装置、ならびにそのプログラム・記憶媒体 |
| US20040242972A1 (en) * | 2003-05-28 | 2004-12-02 | General Electric Company | Method, system and computer product for prognosis of a medical disorder |
| US20050059024A1 (en) | 2003-07-25 | 2005-03-17 | Ambion, Inc. | Methods and compositions for isolating small RNA molecules |
| US20050060295A1 (en) * | 2003-09-12 | 2005-03-17 | Sensory Networks, Inc. | Statistical classification of high-speed network data through content inspection |
| CA2549971A1 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| CA2554836A1 (en) | 2004-02-05 | 2005-08-25 | Medtronic, Inc. | Methods and apparatus for identifying patients at risk for life threatening arrhythmias |
| US7759079B2 (en) * | 2004-05-13 | 2010-07-20 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20060154276A1 (en) | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| AU2005314089B2 (en) * | 2004-12-08 | 2011-03-03 | Cedars-Sinai Medical Center | Methods for diagnosis and treatment of Crohn's disease |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
| US8153443B2 (en) * | 2007-05-10 | 2012-04-10 | Cedars-Sinai Medical Center | Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease |
| WO2010056682A2 (en) * | 2008-11-11 | 2010-05-20 | Prometheus Laboratories Inc. | Methods for prediction of inflammatory bowel disease (ibd) using serologic markers |
| US9434771B2 (en) | 2008-12-17 | 2016-09-06 | The Johns Hopkins University | Compositions and methods for diagnosing and treating inflammatory bowel disease and related disorders |
| US20120171672A1 (en) | 2009-04-14 | 2012-07-05 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
| NZ595471A (en) | 2009-04-14 | 2014-01-31 | Nestec Sa | Inflammatory bowel disease prognostics |
| CA2766157A1 (en) | 2009-06-25 | 2010-12-29 | Hua Gong | Methods for diagnosing irritable bowel syndrome |
| JP2013511988A (ja) | 2009-11-25 | 2013-04-11 | ネステク ソシエテ アノニム | 過敏性腸症候群診断用の新規なゲノムバイオマーカー |
| EP2769321B1 (en) | 2011-10-21 | 2016-06-01 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
-
2010
- 2010-04-13 NZ NZ595471A patent/NZ595471A/en not_active IP Right Cessation
- 2010-04-13 ES ES10713793.7T patent/ES2553415T3/es active Active
- 2010-04-13 EP EP15157904.2A patent/EP2960342A1/en not_active Withdrawn
- 2010-04-13 CA CA2758531A patent/CA2758531C/en active Active
- 2010-04-13 WO PCT/US2010/030934 patent/WO2010120814A1/en not_active Ceased
- 2010-04-13 EP EP10713793.7A patent/EP2419529B1/en active Active
- 2010-04-13 BR BRPI1013560A patent/BRPI1013560A2/pt not_active Application Discontinuation
- 2010-04-13 NZ NZ619527A patent/NZ619527A/en not_active IP Right Cessation
- 2010-04-13 AU AU2010236568A patent/AU2010236568B2/en not_active Ceased
- 2010-08-05 US US12/851,517 patent/US9732385B2/en active Active
-
2011
- 2011-10-06 IL IL215619A patent/IL215619A/en not_active IP Right Cessation
-
2015
- 2015-07-21 IL IL240082A patent/IL240082A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL215619A0 (en) | 2012-01-31 |
| EP2419529B1 (en) | 2015-05-20 |
| ES2553415T3 (es) | 2015-12-09 |
| EP2960342A1 (en) | 2015-12-30 |
| CA2758531A1 (en) | 2010-10-21 |
| US9732385B2 (en) | 2017-08-15 |
| NZ595471A (en) | 2014-01-31 |
| AU2010236568A1 (en) | 2011-11-03 |
| CA2758531C (en) | 2018-11-13 |
| IL215619A (en) | 2016-02-29 |
| AU2010236568B2 (en) | 2015-08-27 |
| IL240082A0 (en) | 2015-08-31 |
| EP2419529A1 (en) | 2012-02-22 |
| NZ619527A (en) | 2015-06-26 |
| WO2010120814A1 (en) | 2010-10-21 |
| US20110045476A1 (en) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201001486B (en) | Diagnosis,staging and monitoring of inflammatory bowel disease | |
| BR112013016202A2 (pt) | fluidos de perfuração tendo potencial de deformação reduzido e métodos relacionados | |
| BRPI0718945A2 (pt) | Novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção | |
| BRPI0911998A2 (pt) | métodos e kits para o tratamento de condições de desordem inflamatória intestinal | |
| EP2997162A4 (en) | Methods for diagnosing and treating inflammatory bowel disease | |
| GB2435118C (en) | Multiprocessor system and boot-up method of slave system. | |
| BRPI0910608A2 (pt) | métodos e sistemas para avaliar resultados clínicos | |
| IL233096A0 (en) | Ratio based biomarkers and methods of use thereof | |
| EP2635295A4 (en) | CONTROL AND CHARACTERIZATION OF MEMORY FUNCTIONS | |
| BR112012003061A2 (pt) | estruturas fibrosas e métodos para fabricação das mesmas | |
| BRPI1015026A2 (pt) | método e aparelho para facilitar os procedimentos de medição em operação de multiportadora. | |
| BR112012002955A2 (pt) | estruturas fibrosas e métodos de fabricação das mesmas. | |
| BRPI0822374A2 (pt) | aparelhos e métodos para avaliar uma pessoa para um sistema de sono | |
| BRPI0821145A2 (pt) | Agente terapêutico para prurido | |
| BR112013001875A2 (pt) | cueca masculina com espaço separado para o pênis | |
| IL215619A (en) | Prognosis of infectious bowel disease | |
| IT1397197B1 (it) | Veicolo battipista e relativo metodo di controllo. | |
| BRPI0820885A2 (pt) | Composições e métodos para diagnóstico precoce de gravidez | |
| BR112012002238A2 (pt) | método para executar uma função cooperativa, dispositivo para executar automaticamente uma função cooperativa com outro dispositivo, e sistema para executar automaticamente uma função cooperativa | |
| DK2430452T3 (da) | Carcinom-diagnose og behandlinger, baseret på odc1-genotype | |
| BR112013014479A2 (pt) | método melhorado e kit para determinar a gravidade e progressão da doença periodontal | |
| EP2903629A4 (en) | ASSOCIATED WITH INFLAMMATORY DARMINARY ANTIGENES | |
| BRPI1015927A2 (pt) | Kit e método para diagnosticar uma doença de tireoide e método para diagnosticar o hipotireoidismo, bem como célula e seu uso | |
| ZA202000242B (en) | Targeted defa5 antibody and assay methods for diagnosing and treating inflammatory bowel disease | |
| EP2140261A4 (en) | METHODS AND AGENTS FOR ASSESSING INFLAMMATORY ABDOMINAL INFECTION AND TARGETS FOR TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NESTEC S.A. (CH) |
|
| B25A | Requested transfer of rights approved |
Owner name: NESTEC S.A. (CH) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: NESTEC S.A. (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |